News
11-15-2011, 03:11 AM
Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, being held Nov. 12-16, 2011...
More... (http://www.medicalnewstoday.com/releases/237643.php)
More... (http://www.medicalnewstoday.com/releases/237643.php)